OBJECTIVE: To investigate the prevalence of celiac disease in a large cohort of children and adolescents at the onset of type 1 diabetes and the occurrence of new cases during a 6-year follow-up. METHODS: We prospectively studied, by repeated serologic screening, 274 consecutive patients at the onset of type 1 diabetes (age [mean +/- standard deviation]: 8.28 +/- 4.65 years) for 6 subsequent years. One patient had a diagnosis of celiac disease before the onset of diabetes. The immunoglobulin A-antiendomysium antibody test was selected as the screening test; patients with positive results (++ or +++) or with 2 consecutive weak positive tests (+) were considered appropriate for the jejunal biopsy. RESULTS: At diabetes onset, 15 (5.5%) of 273 patients tested positive with the antiendomysium test; jejunal biopsy was performed in 10, and celiac disease was diagnosed in 9. The prevalence of biopsy-confirmed celiac disease at the manifestation of diabetes was 3.6% (10 of 274 patients). Twelve more patients with a negative antiendomysium antibody test at diabetes onset tested positive during the follow-up within 4 years; 10 of them had biopsies performed, and 7 had celiac disease. Therefore, the overall prevalence of biopsy-confirmed celiac disease in the entire cohort of patients was 6.2%. The age at diabetes onset in patients with and without celiac disease was not different (7.88 +/- 5.69 vs 8.3 +/- 4.58 years). The majority of cases of celiac disease were asymptomatic in their presentation, and no signs of overt malnutrition were documented. CONCLUSIONS: The prevalence of celiac disease in patients with type 1 diabetes is approximately 20 times higher than in the general population. Sixty percent of cases are already present at diabetes onset, mostly undetected, but an additional 40% of patients develop celiac disease a few years after diabetes onset. Extending screening programs for celiac disease after the onset of type 1 diabetes is recommended, even in the absence of clinical symptoms.
OBJECTIVE: To investigate the prevalence of celiac disease in a large cohort of children and adolescents at the onset of type 1 diabetes and the occurrence of new cases during a 6-year follow-up. METHODS: We prospectively studied, by repeated serologic screening, 274 consecutive patients at the onset of type 1 diabetes (age [mean +/- standard deviation]: 8.28 +/- 4.65 years) for 6 subsequent years. One patient had a diagnosis of celiac disease before the onset of diabetes. The immunoglobulin A-antiendomysium antibody test was selected as the screening test; patients with positive results (++ or +++) or with 2 consecutive weak positive tests (+) were considered appropriate for the jejunal biopsy. RESULTS: At diabetes onset, 15 (5.5%) of 273 patients tested positive with the antiendomysium test; jejunal biopsy was performed in 10, and celiac disease was diagnosed in 9. The prevalence of biopsy-confirmed celiac disease at the manifestation of diabetes was 3.6% (10 of 274 patients). Twelve more patients with a negative antiendomysium antibody test at diabetes onset tested positive during the follow-up within 4 years; 10 of them had biopsies performed, and 7 had celiac disease. Therefore, the overall prevalence of biopsy-confirmed celiac disease in the entire cohort of patients was 6.2%. The age at diabetes onset in patients with and without celiac disease was not different (7.88 +/- 5.69 vs 8.3 +/- 4.58 years). The majority of cases of celiac disease were asymptomatic in their presentation, and no signs of overt malnutrition were documented. CONCLUSIONS: The prevalence of celiac disease in patients with type 1 diabetes is approximately 20 times higher than in the general population. Sixty percent of cases are already present at diabetes onset, mostly undetected, but an additional 40% of patients develop celiac disease a few years after diabetes onset. Extending screening programs for celiac disease after the onset of type 1 diabetes is recommended, even in the absence of clinical symptoms.
Authors: L Nisticò; C Fagnani; I Coto; S Percopo; R Cotichini; M G Limongelli; F Paparo; S D'Alfonso; M Giordano; C Sferlazzas; G Magazzù; P Momigliano-Richiardi; L Greco; M A Stazi Journal: Gut Date: 2005-12-14 Impact factor: 23.059
Authors: Farid H Mahmud; Joseph A Murray; Yogish C Kudva; Alan R Zinsmeister; Ross A Dierkhising; Brian D Lahr; Peter J Dyck; Robert A Kyle; Mounif El-Youssef; Lawrence J Burgart; Carol T Van Dyke; Deanna L Brogan; L Joseph Melton Journal: Mayo Clin Proc Date: 2005-11 Impact factor: 7.616
Authors: Alexandra Zhernakova; Behrooz Z Alizadeh; Marianna Bevova; Miek A van Leeuwen; Marieke J H Coenen; Barbara Franke; Lude Franke; Marcel D Posthumus; David A van Heel; Gerrit van der Steege; Timothy R D J Radstake; Pilar Barrera; Bart O Roep; Bobby P C Koeleman; Cisca Wijmenga Journal: Am J Hum Genet Date: 2007-10-24 Impact factor: 11.025
Authors: Katharina Warncke; Elke E Fröhlich-Reiterer; Angelika Thon; Sabine E Hofer; Dagobert Wiemann; Reinhard W Holl Journal: Diabetes Care Date: 2010-06-14 Impact factor: 19.112
Authors: Satu Simell; Sanna Hoppu; Tuu Simell; Marja-Riitta Ståhlberg; Markku Viander; Taina Routi; Ville Simell; Riitta Veijola; Jorma Ilonen; Heikki Hyöty; Mikael Knip; Olli Simell Journal: Diabetes Care Date: 2010-01-07 Impact factor: 19.112